Device Trial Radar · NCT05899478
Suture-mediated Closure System Following Endovascular Peripheral Arterial Procedures
Last checked: Nov 20, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
135
Actual
Start
Jun 1, 2023
Primary completion
Jan 1, 2024
Study completion Apr 1, 2024
Sponsor
- Lead sponsor
- Suzhou Hengruihongyuan Medical Technology Co. LTDNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 12, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effectiveness and safety of the suture-mediated closure system produced by Suzhou Hengrui Hongyuan Medical Technology Co., Ltd. following endovascular peripheral arterial procedures.
Conditions
- Percutaneous Intervention Via Femoral Artery
Interventions
Tyknot® Suture-Mediated Closure SystemDevice
Arterial closure to ensure hemostasis at femoral artery puncture points
Perclose® ProGlide Suture-Mediated Closure SystemDevice
Arterial closure to ensure hemostasis at femoral artery puncture points
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of successful hemostasisTime frame: 10 minutes
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of USTC
Hefei, Anhui, China
Zhongshan Hospital
Shanghai, Shanghai Municipality, China
Affiliated Hangzhou First People's Hospital ,Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.